Lantern Pharma's LP-184 Receives Orphan Drug Tag For Brain Cancer Indication

by Vandana Singh, Benzinga Editor

August 30, 2021 11:02 AM | 1 min read |

The FDA has granted Orphan Drug Designation to Lantern Pharma Inc's LTRN LP-184 for glioblastoma multiforme (GBM) and other malignant gliomas.
The news follows the recent announcement of the FDA granting LP-184 Orphan Drug tag for pancreatic cancer.
LP-184 is a small molecule drug candidate and next-generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or harbor mutations in DNA repair pathways.
Related Content: LP-184 Inhibits Tumor Growth, Improves Survival In Animals Models Of Glioblastoma
Related content: Benzinga's Full FDA Calendar
Price action: LTRN shares are down 1.14% at $13.90 during the market session on the last check Monday.

Posted In: Biotech News Health Care FDA Movers Trading Ideas General Briefs glioblastoma Orphan Drug Designation

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.